At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Pioglitazone 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
In Brief
A Phase 2 clinical trial evaluating Pioglitazone for Depressive Disorder, Major and Metabolic Syndrome X. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid Metabolic Syndrome (METSYN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major, Metabolic Syndrome X
CountriesUnited States
CollaboratorsTakeda Pharmaceuticals North America, Inc.
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionAug 2011
Study CompletionNov 2011
TodayJul 2026
First PostedMay 5, 2008
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2011
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.2 years ago
Interventions
Pioglitazonedrug
An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.